JP2002500181A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002500181A5 JP2002500181A5 JP2000527236A JP2000527236A JP2002500181A5 JP 2002500181 A5 JP2002500181 A5 JP 2002500181A5 JP 2000527236 A JP2000527236 A JP 2000527236A JP 2000527236 A JP2000527236 A JP 2000527236A JP 2002500181 A5 JP2002500181 A5 JP 2002500181A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- riluzole
- per day
- composition according
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 9
- 229960004181 riluzole Drugs 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- WTDRDQBEARUVNC-LURJTMIESA-N 3-hydroxy-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- 229940107161 Cholesterol Drugs 0.000 description 2
- 208000001187 Dyskinesias Diseases 0.000 description 2
- 206010043118 Tardive dyskinesia Diseases 0.000 description 2
- 230000000561 anti-psychotic Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229960004502 levodopa Drugs 0.000 description 2
Description
【特許請求の範囲】
【請求項１】 レボドパ、有効量のリルゾール、および製薬学的に許容されるキャリアーを含んで成る、医薬組成物。
【請求項２】 抗精神病薬、有効量のリルゾール、および製薬学的に許容されるキャリアーを含んで成る、医薬組成物。
【請求項３】 レボドパが誘起するジスキネジーおよび遅発性ジスキネジー
を改善するためのリルゾールを含んで成る医薬組成物。
【請求項４】 １日あたり約２５〜約２００ｍｇのリルゾールを投与するための請求項３記載の医薬組成物。
【請求項５】 １日あたり約５０〜約２００ｍｇのリルゾールを投与するための請求項４記載の医薬組成物。
【請求項６】 １日あたり約５０〜約１００ｍｇのリルゾールを投与するための請求項５記載の医薬組成物。
【請求項７】 抗精神病薬が誘起するジスキネジーおよび遅発性ジスキネジー
を改善するためのリルゾールを含んで成る医薬組成物。
【請求項８】 １日あたり約２５〜約２００ｍｇのリルゾールを投与するための請求項７記載の医薬組成物。
【請求項９】 １日あたり約５０〜約２００ｍｇのリルゾールを投与するための請求項８記載の医薬組成物。
【請求項１０】 １日あたり約５０〜約１００ｍｇのリルゾールを投与するための請求項９記載の医薬組成物。
[Claims]
(1) Levodopa,EffectivenessQuantityRiluzole,And a pharmaceutically acceptable carrier,Pharmaceutical composition.
(2) Comprising an antipsychotic, an effective amount of riluzole, and a pharmaceutically acceptable carrier,Pharmaceutical composition.
(3) Levodopa-induced dyskinesia and tardive dyskinesia
Pharmaceutical composition comprising riluzole for improving cholesterol.
Claims4The use of about 25 to about 200 mg of riluzole per dayNoRequest3The pharmaceutical composition according to any one of the preceding claims.
Claims5] 5. The pharmaceutical composition according to claim 4, for administering about 50 to about 200 mg of riluzole per day.
Claims6] 6. The pharmaceutical composition according to claim 5, for administering about 50 to about 100 mg of riluzole per day..
Claims7] Antipsychotic-induced dyskinesia and tardive dyskinesia
Pharmaceutical composition comprising riluzole for improving cholesterol.
Claims8] 8. The pharmaceutical composition according to claim 7, for administering about 25 to about 200 mg of riluzole per day..
Claims9] 9. The pharmaceutical composition according to claim 8, for administering about 50 to about 200 mg of riluzole per day.
Claims10] 10. The pharmaceutical composition according to claim 9, for administering about 50 to about 100 mg of riluzole per day..
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL122883 | 1998-01-09 | ||
| IL12288398A IL122883A0 (en) | 1998-01-09 | 1998-01-09 | Pharmaceutical compositions for the treatment of dyskinesias |
| IL127102 | 1998-11-17 | ||
| IL12710298A IL127102A0 (en) | 1998-11-17 | 1998-11-17 | Pharmaceutical compositions for the treatment of dyskinesias |
| PCT/IL1999/000003 WO1999034785A2 (en) | 1998-01-09 | 1999-01-05 | Treatment of dyskinesias |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002500181A JP2002500181A (en) | 2002-01-08 |
| JP2002500181A5 true JP2002500181A5 (en) | 2006-03-02 |
Family
ID=26323572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000527236A Pending JP2002500181A (en) | 1998-01-09 | 1999-01-05 | Dyskinesia treatment |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1043996A2 (en) |
| JP (1) | JP2002500181A (en) |
| KR (1) | KR20010033978A (en) |
| CN (1) | CN1290166A (en) |
| AU (1) | AU1780699A (en) |
| BR (1) | BR9906821A (en) |
| CA (1) | CA2317811A1 (en) |
| NO (1) | NO20003529L (en) |
| PL (1) | PL342098A1 (en) |
| WO (1) | WO1999034785A2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000054772A1 (en) * | 1999-03-12 | 2000-09-21 | Aventis Pharma S.A. | Amyotropic lateral sclerosis treatment with a combination of riluzole and an ampa receptor antagonist |
| FR2790670A1 (en) * | 1999-03-12 | 2000-09-15 | Aventis Pharma Sa | Treatment or prevention of amyotrophic lateral sclerosis, using synergistic combination of riluzole and AMPA receptor antagonist, e.g. 5H,10H-imidazo (1,2-a) indeno (1,2-e) pyrazin-4-one derivative |
| FR2801793B1 (en) * | 1999-12-01 | 2003-07-04 | Aventis Pharma Sa | COMBINATION OF ERGOLIN AND RILUZOLE AND ITS USE AS A MEDICINAL PRODUCT |
| US6297254B1 (en) | 1999-12-01 | 2001-10-02 | Aventis Pharma S. A. | Method for the prevention or treatment of a motoneuron disease |
| FR2809620B1 (en) * | 2000-06-05 | 2002-08-02 | Aventis Pharma Sa | USE OF RILUZOLE OR ITS SALTS FOR THE PREVENTION AND TREATMENT OF ADRENOLEUCODYSTROPHY |
| EP1325742A1 (en) * | 2001-05-08 | 2003-07-09 | Schwarz Pharma Ag | Improved transdermal therapeutic system for the treatment of Parkinson's disease |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2688138B1 (en) * | 1992-03-06 | 1995-05-05 | Rhone Poulenc Rorer Sa | APPLICATION OF AMINO-2 TRIFLUOROMETHOXY-6 BENZOTHIAZOLE TO OBTAIN A MEDICINE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS. |
| FR2700117B1 (en) * | 1993-01-07 | 1995-02-03 | Rhone Poulenc Rorer Sa | Application of anti-convulsants in the treatment of Parkinson's disease and parkinsonian syndromes. |
-
1999
- 1999-01-05 AU AU17806/99A patent/AU1780699A/en not_active Abandoned
- 1999-01-05 PL PL99342098A patent/PL342098A1/en unknown
- 1999-01-05 WO PCT/IL1999/000003 patent/WO1999034785A2/en not_active Application Discontinuation
- 1999-01-05 CN CN99802790A patent/CN1290166A/en active Pending
- 1999-01-05 EP EP99900116A patent/EP1043996A2/en not_active Withdrawn
- 1999-01-05 CA CA002317811A patent/CA2317811A1/en not_active Abandoned
- 1999-01-05 BR BR9906821-4A patent/BR9906821A/en not_active IP Right Cessation
- 1999-01-05 KR KR1020007007567A patent/KR20010033978A/en not_active Application Discontinuation
- 1999-01-05 JP JP2000527236A patent/JP2002500181A/en active Pending
-
2000
- 2000-07-07 NO NO20003529A patent/NO20003529L/en not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004056337A3 (en) | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats | |
| YU37301A (en) | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent | |
| JO2555B1 (en) | Oral dosage forms for propiverine or pharmaceutically acceptable salts thereof having prolonged release of the active agent | |
| NZ514574A (en) | Novel method of treatment | |
| WO2001019337A3 (en) | Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing | |
| AU2277101A (en) | Stable extended release oral dosage composition | |
| AU2001283563A1 (en) | Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent | |
| AU7375598A (en) | Stable oral pharmaceutical dosage forms | |
| HK1050839A1 (en) | Use of pharmaceutical compositions comprising oxcarbazepine in the fasted state | |
| SG127714A1 (en) | Method of treating metabolic disorders, especiallydiabetes, or a disease or condition associated wi th diabetes | |
| JP2002511411A5 (en) | ||
| YU14502A (en) | Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive | |
| AU1724301A (en) | Hydrogel-driven layered drug dosage form | |
| JP2002524415A5 (en) | ||
| AU9018898A (en) | Phosphazole-containing nucleoside analogs, related compounds, pharmaceutical compositions thereof, and their use in in vitro medicinal treatments | |
| HK1045113A1 (en) | Oral administration form for administering a fixed tramadol and diclofenac combination | |
| AU2003238221A1 (en) | Ibuprofen suspension | |
| CA2325739A1 (en) | Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator | |
| ZA200308221B (en) | Pharmaceutical compositions for oral and topical administration. | |
| BR0013719A (en) | Controlled-release oral dosage, suitable for oral administration | |
| WO2006004449A3 (en) | A combination composition | |
| JP2002522501A5 (en) | ||
| CA2283255A1 (en) | Use of r-nsaid's for the prevention of alzheimer's disease | |
| CA2350659A1 (en) | Pharmaceutical composition for modified release insulin sensitiser | |
| JP2002500181A5 (en) |